中華民國血液病學會

▪67-year-old male patient was diagnosed as WM

Serum electropheresis findings

1. Which statement is true?

A. IPSSWM score: high risk; 5-year OS: 70%.

B. rIPSSWM score: intermediate risk; 5-year OS:47%.

C. French score: high risk; 5-year OS: 25%.

D. All above.

2. Which statement is WM specific in WHO criteria?

A. Neoplasm of small B lymphocytes, plasmacytoid lymphocytes, and plasma cells.

B. Usually involving bone marrow and sometimes lymph nodes and spleen.

C. Does not fulfill criteria of any other small B-cell lymphoid neoplasm that may also have plasmacytic differentiation.

D. LPL With bone marrow involvement and IgM monoclonal gammopathy of any concentration.

3. Which statement is false?

A. Zanubrutinib, Acalabrutinib, and Ibrutinib were approved by FDA for treating WM.

B. Zanubrutinib and Ibrutinib were approved for treating both TN and RR WM.

C. According to results of ASPEN substudy demonstrate that zanubrutinib monotherapy can induce high quality responses in patients with MYD88WT WM.

D. MYD88WT and CXCR4mut are the indicators for poor survival in WM.